echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Chemicals Industry > China Chemical > How should pharmaceutical companies respond to the upgrading of anti-monopoly supervision of APIs?

    How should pharmaceutical companies respond to the upgrading of anti-monopoly supervision of APIs?

    • Last Update: 2021-12-05
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    [ Focus on Chemical Machinery and Equipment Network ] In order to prevent and stop monopolistic activities in the field of APIs, further clarify the rules of market competition, maintain the order of market competition in the field of APIs, and protect the interests of consumers and the public interest, the National Anti-Monopoly Commission has recently officially announced Antitrust guidelines in the field of APIs
    .

     
    Chemical machinery and equipment network hotspots pay attention to chemical machinery and equipment
    From the content point of view, the "Guide" is divided into six chapters and 29 articles, which mainly stipulate the five aspects of general principles, monopoly agreements, abuse of dominant market position, concentration of operators, abuse of administrative power to exclude, and restriction of competition
    .
    Among them, the guide also highlights its application to the upstream chemical raw materials and pharmaceutical intermediates required for the production of APIs and pharmaceutical excipients
    .

     

    The industry believes that the formulation and promulgation of this guide will further improve the rules of the anti-monopoly supervision system, which will help enhance the uniformity, scientificity and effectiveness of anti-monopoly law enforcement in the field of APIs, and improve the predictability and transparency of law enforcement
    .
    At the same time, it is also beneficial for operators in the API field to clarify the boundaries of behavior, strengthen compliance and self-discipline in accordance with the law, and reduce the risk of violations
    .

     

    It is understood that monopolistic behaviors of APIs have occurred from time to time.
    After some APIs are monopolized, they will directly affect the normal production behavior of downstream preparation companies.
    In addition, when faced with monopoly, some companies cannot afford the cost.
    Due to pressures such as rising, production has to be cut or even stopped, which also harms the interests of patients
    .
    Therefore, in order to say no to the monopoly of APIs, the country and localities have been issuing policies and regulations in recent years to curb the monopoly of APIs and effectively maintain the order of competition in the API market
    .
    For example, in February this year, the state clearly stated in the "Action Plan for Building a High-Standard Market System" that it should formulate anti-monopoly guidelines and guidelines for the application of the exemption system in specific areas such as APIs
    .

     

      However, some people in the industry pointed out that the control of monopoly chaos in China’s API market cannot be solved overnight.
    Policy assistance alone can be used to solve the problem.
    It requires multi-faceted efforts to give full play to market mechanisms and improve legal rules to reduce market entry.
    Barriers, increase penalties in the API industry, and innovate law enforcement methods.
    At the same time, relevant companies should be encouraged to use technological innovation as the main method of competition to effectively safeguard the interests of consumers and the public
    .

     

      In general, judging from the anti-monopoly cases that have been disclosed so far, compared with the past, the anti-monopoly law enforcement against the pharmaceutical industry is becoming larger and wider
    .
    In this regard, as a raw material drug company, when developing and expanding, it must first avoid sales control, especially monopolistic behaviors such as fixing the resale of drugs and limiting the resale of drugs to low resale
    .
    Secondly, pharmaceutical companies must always pay attention to relevant laws and regulations, standardize production behavior, and operate in compliance with regulations, so that they can continue to develop in a healthy manner and avoid monopolistic behaviors
    .

     

      In addition to the above suggestions, some people in the industry have suggested that if pharmaceutical companies want to continue to pursue higher profits while avoiding monopoly, they can also invest more in branding and pharmaceutical services, such as using Internet platforms to expand.
    sales channels and better customer service and so on
    .

     

      Original title: How should pharmaceutical companies respond to the upgrading of anti-monopoly supervision of APIs?
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.